Collaborations & Alliances

Compugen Earns $6M AstraZeneca Milestone in Antibody Alliance

First patient dosed in Phase 1/2 study of AZD2936 in advanced or metastatic non-small cell lung cancer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Compugen Ltd., a clinical-stage cancer immunotherapy company will receive a $6 million milestone payment from AstraZeneca triggered by the dosing of the first patient in a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer. AZD2936 is derived from COM902, Compugen’s high-affinity clinical-stage anti-TIGIT antibody.   “We are proud that AstraZeneca’s TIGIT bispecific program, derived from COM...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters